Amyloid-beta zinc-binding site (Zn-Aβ)

The Amyloid-beta (Aβ) zinc-binding site is a critical molecular interface involved in the pathogenesis of Alzheimer's disease (nih.gov, 2011). Zinc ions (Zn2+) coordinate with the N-terminal region of Aβ peptides, primarily through residues His6, His13, His14, and Glu11 (nih.gov, 2011; acs.org, 2022). Under physiological conditions, zinc is co-released with glutamate at synapses and plays a role in modulating synaptic plasticity (nih.gov, 2021). However, in the context of Alzheimer's, high concentrations of zinc promote the rapid aggregation of Aβ into neurotoxic oligomers and insoluble plaques, which are resistant to proteolytic degradation (mdpi.com, 2022; acs.org, 2008). Therapeutic interventions targeting this interface, such as Metal-Protein Attenuating Compounds (MPACs) like PBT2 and Clioquinol, aim to sequester zinc from Aβ (nih.gov, 2011; nih.gov, 2022). This action inhibits the formation of toxic aggregates, facilitates Aβ clearance by enzymes like matrix metalloproteinase-2 (MMP-2), and redistributes zinc into neurons to support cognitive function (nih.gov, 2011). Despite promising preclinical results, these agents have faced challenges in clinical trials regarding efficacy and safety (acs.org, 2022).

Other names

Zinc-Amyloid-beta complexAβ metal-binding domainZinc-Aβ interfaceAmyloid-beta metal-binding interfaceZn-Aβ complex

Metal-protein attenuation (MPA) involving the chelation and redistribution of zinc and copper ions from amyloid-beta (Aβ) complexes. This process inhibits Aβ aggregation into toxic oligomers, promotes the degradation of Aβ by matrix metalloproteinases (e.g., MMP-2), and restores neuronal metal homeostasis to support synaptic function.